SCHEMBL3602873

SCHEMBL3602873

CS(=O)(=O)OCc1cccc(OC[C@H]2CCCN2C(=O)O)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAGLB Q8NCG7 1/20 0.40
GRM5 P41594 1/20 0.36
GRM1 Q13255 1/20 0.36
CYP2D6 P10635 2/20 0.36
DPP4 P27487 2/20 0.36
DPP8 Q6V1X1 2/20 0.36
DPP9 Q86TI2 2/20 0.36
DPP7 Q9UHL4 2/20 0.36
CNR2 P34972 1/20 0.36
SPHK2 Q9NRA0 1/20 0.36
CHRNB2 P17787 2/20 0.35
CHRNA4 P43681 2/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA7 P36544 1/20 0.34
ABHD6 Q9BV23 1/20 0.34
DAGLA Q9Y4D2 1/20 0.34
SPHK1 Q9NYA1 1/20 0.34
EGFR P00533 1/20 0.34
ERBB2 P04626 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3608576 0.97 DAGLB (0.43) DAGLBGRM5GRM1CYP2D6DPP4
SCHEMBL3606003 0.84 CNR2 (0.40) GRM5GRM1CYP2D6DPP4DPP8
SCHEMBL3607859 0.83 CYP2D6 (0.38) GRM5GRM1CYP2D6DPP4DPP8
SCHEMBL3615900 0.81 CNR2 (0.42) CYP2D6DPP4DPP8DPP9DPP7
SCHEMBL3605764 0.80 RAB9A (0.39) CYP2D6DPP4DPP8DPP9DPP7
SCHEMBL2788731 0.76 POLB (0.41) DAGLBDPP4CHRNB2CHRNA4CHRNA7
SCHEMBL2546757 0.76 POLB (0.41) DAGLBDPP4CHRNB2CHRNA4CHRNA7
SCHEMBL793131 0.76 POLB (0.41) DAGLBDPP4CHRNB2CHRNA4CHRNA7
SCHEMBL3602342 0.74 GPR119 (0.39)
SCHEMBL15653975 0.72 DAGLB (0.40) DAGLBABHD6DAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723331-B2 Thienopyrimidine compounds and uses thereof ASTRAZENECA AB (SE) 2010-05-25 US disclosed
EP-2121703-A1 THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS AstraZeneca AB (SE) 2009-11-25 EP disclosed
US-20080051405-A1 Therapeutic Agents ASTRAZENECA AB (SE) 2008-02-28 US disclosed
WO-2008020799-A1 THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS ASTRAZENECA AB (SE) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051405-A1 Therapeutic Agents GPR119, HTT, IAPP DAGLB 829/4885GRM5 73/4885GRM1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.